Azumolene sodium anhydrous | CAS# 105336-14-9 | Biochemical

MedKoo Cat#: 575246 | Name: Azumolene sodium anhydrous

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Azumolene sodium anhydrous is a muscle relaxant that inhibits the release of calcium from skeletal muscle sarcoplasmic reticulum. Azumolene inhibits a component of store-operated calcium entry coupled to the skeletal muscle ryanodine receptor. Azumolene, an equipotent dantrolene analog, inhibits a component of SOCE coupled to activation of RyR1 by caffeine and ryanodine, whereas the SOCE component induced by thapsigargin is not affected.

Chemical Structure

Azumolene sodium anhydrous

CAS#105336-14-9 (sodium)

Theoretical Analysis

MedKoo Cat#: 575246

Name: Azumolene sodium anhydrous

CAS#: 105336-14-9 (sodium)

Chemical Formula: C13H8BrN4NaO3

Exact Mass: 0.0000

Molecular Weight: 371.13

Elemental Analysis: C, 42.07; H, 2.17; Br, 21.53; N, 15.10; Na, 6.19; O, 12.93

Price and Availability

Size	Price	Availability	Quantity
5mg	USD 385.00	2 Weeks
10mg	USD 685.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

64748-79-4 (free) 105336-14-9 (sodium) 91524-18-4 (sodium hydrate)

Synonym

Azumolene sodium anhydrous

IUPAC/Chemical Name

2,4-Imidazolidinedione, 1-(((5-(4-bromophenyl)-2-oxazolyl)methylene)amino)-, sodium salt

InChi Key

PHJRJPWBPXLNAJ-FPUQOWELSA-M

InChi Code

InChI=1S/C13H9BrN4O3.Na/c14-9-3-1-8(2-4-9)10-5-15-12(21-10)6-16-18-7-11(19)17-13(18)20;/h1-6H,7H2,(H,17,19,20);/q;+1/p-1/b16-6+;

SMILES Code

[Na+].Brc1ccc(cc1)c2oc(\C=N\N3CC(=O)[N-]C3=O)nc2

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 371.13 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Si D, Azam MA, Lai PFH, Zamiri N, Kichigina G, Asta J, Massé S, Bokhari MM, Porta-Sánchez A, Labos C, Sun H, Yang P, Nanthakumar K. Essential role of ryanodine receptor 2 phosphorylation in the effect of azumolene on ventricular arrhythmia vulnerability in a rabbit heart model. J Cardiovasc Electrophysiol. 2018 Dec;29(12):1707-1715. doi: 10.1111/jce.13737. Epub 2018 Oct 31. PMID: 30203424. 2: Talbert EE, Smuder AJ, Kwon OS, Sollanek KJ, Wiggs MP, Powers SK. Blockage of the Ryanodine Receptor via Azumolene Does Not Prevent Mechanical Ventilation- Induced Diaphragm Atrophy. PLoS One. 2016 Feb 5;11(2):e0148161. doi: 10.1371/journal.pone.0148161. PMID: 26849371; PMCID: PMC4744044. 3: Zhao X, Min CK, Ko JK, Parness J, Kim DH, Weisleder N, Ma J. Increased store- operated Ca2+ entry in skeletal muscle with reduced calsequestrin-1 expression. Biophys J. 2010 Sep 8;99(5):1556-64. doi: 10.1016/j.bpj.2010.06.050. PMID: 20816068; PMCID: PMC2931717. 4: Zhao X, Weisleder N, Han X, Pan Z, Parness J, Brotto M, Ma J. Azumolene inhibits a component of store-operated calcium entry coupled to the skeletal muscle ryanodine receptor. J Biol Chem. 2006 Nov 3;281(44):33477-86. doi: 10.1074/jbc.M602306200. Epub 2006 Aug 31. PMID: 16945924. 5: McKinney LC, Butler T, Mullen SP, Klein MG. Characterization of ryanodine receptor-mediated calcium release in human B cells: relevance to diagnostic testing for malignant hyperthermia. Anesthesiology. 2006 Jun;104(6):1191-201. doi: 10.1097/00000542-200606000-00014. PMID: 16732090. 6: Zhang Y, Rodney GG, Schneider MF. Effects of azumolene on Ca2+ sparks in skeletal muscle fibers. J Pharmacol Exp Ther. 2005 Jul;314(1):94-102. doi: 10.1124/jpet.105.084046. Epub 2005 Apr 14. PMID: 15831441. 7: Kindler CH, Eilers H, Donohoe P, Ozer S, Bickler PE. Volatile anesthetics increase intracellular calcium in cerebrocortical and hippocampal neurons. Anesthesiology. 1999 Apr;90(4):1137-45. doi: 10.1097/00000542-199904000-00029. PMID: 10201687. 8: Shamash J, Salam AH, Davies DC, Williams A, Joel S, Lister TA. In vitro testing of calcium channel blockers and cytotoxic chemotherapy in B-cell low- grade non-Hodgkin's lymphoma. Br J Cancer. 1998 May;77(10):1598-603. doi: 10.1038/bjc.1998.262. PMID: 9635834; PMCID: PMC2150073. 9: Palnitkar SS, Mickelson JR, Louis CF, Parness J. Pharmacological distinction between dantrolene and ryanodine binding sites: evidence from normal and malignant hyperthermia-susceptible porcine skeletal muscle. Biochem J. 1997 Sep 15;326 ( Pt 3)(Pt 3):847-52. doi: 10.1042/bj3260847. PMID: 9307036; PMCID: PMC1218741.